文献速递泌尿生殖腹部CT

基于影像组学的预测模型用于预测转移性尿路上皮癌PD-1/PD-L1免疫治疗结局

Radiomics-based prediction model for outcomes of PD-1/PD-L1 immunotherapy in metastatic urothelial carcinoma.
PubMed 文献 · Eur Radiol · 2020-05-12

研究纳入62例接受PD-1/PD-L1免疫治疗的转移性尿路上皮癌患者,在增强CT上勾画224个可测量病灶构建影像组学模型(5个可靠影像组学特征+内脏器官受累),验证集中预测客观缓解和疾病控制的AUC分别为0.87和0.88,高风险组无进展生存和总生存均较短。

要点

  • 基于增强CT影像组学特征联合内脏器官受累的模型,在验证集预测客观缓解AUC为0.87(95%CI 0.65-0.97)。
  • 验证集预测疾病控制AUC为0.88(95%CI 0.67-0.98),决策曲线分析净获益优于无影像组学模型。
  • 验证集高风险组无进展生存和总生存均短于低风险组(log-rank P=0.044和P=0.035)。

核心结论

  • 基于影像组学的模型可能预测转移性尿路上皮癌患者接受PD-1/PD-L1免疫治疗的缓解和生存结局。
  • 该方法可能为规划免疫治疗提供重要的决策工具。

研究设计与样本

  • 回顾性纳入62例接受PD-1/PD-L1免疫治疗的转移性尿路上皮癌患者,分为训练集41例和验证集21例。
  • 在增强CT上识别224个可测量病灶,采用最小绝对收缩和选择算子算法在训练集筛选特征构建影像组学标签。
  • 基于5个可靠影像组学特征和内脏器官受累情况,采用多变量逻辑回归构建影像组学模型。
  • 根据训练集确定的截断值,将验证集患者分为高风险组和低风险组,采用Kaplan-Meier分析比较两组无进展生存和总生存。

诊断标准与关键数值

  • 验证集预测客观缓解的受试者工作特征曲线下面积为0.87(95%CI 0.65-0.97)。
  • 验证集预测疾病控制的受试者工作特征曲线下面积为0.88(95%CI 0.67-0.98)。
  • 决策曲线分析显示,影像组学模型提供的净获益大于无影像组学模型。
  • 验证集高风险组无进展生存和总生存均短于低风险组(log-rank P=0.044和P=0.035)。

临床应用与阅片要点

  • 作者认为,基于增强CT影像组学特征联合内脏器官受累的模型可能用于预测PD-1/PD-L1免疫治疗的缓解和生存结局。
  • 作者认为,该方法可能为规划免疫治疗提供重要的决策工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the usefulness of a radiomics-based prediction model for predicting response and survival outcomes of patients with metastatic urothelial carcinoma treated with immunotherapy targeting programmed cell death 1 (PD-1) and its ligand (PD-L1).

METHODS: Sixty-two patients who underwent immunotherapy were divided into training (n = 41) and validation sets (n = 21). A total of 224 measurable lesions were identified on contrast-enhanced CT. A radiomics signature was constructed with features selected using a least absolute shrinkage and selection operator algorithm in the training set. A radiomics-based model was built based on a radiomics signature consisting of five reliable RFs and the presence of visceral organ involvement using multivariate logistic regression. According to a cutoff determined on the training set, patients in the validation set were assigned to either high- or low-risk groups. Kaplan-Meier analysis was performed to compare progression-free and overall survival between high- and low-risk groups.

RESULTS: For predicting objective response and disease control, the areas under the receiver operating characteristic curves of the radiomics-based model were 0.87 (95% CI, 0.65-0.97) and 0.88 (95% CI, 0.67-0.98) for the validation set, providing larger net benefit determined by decision curve analysis than without radiomics-based model. The high-risk group in the validation set showed shorter progression-free and overall survival than the low-risk group (log-rank p = 0.044 and p = 0.035).

CONCLUSIONS: The radiomics-based model may predict the response and survival outcome in patients treated with PD-1/PD-L1 immunotherapy for metastatic urothelial carcinoma. This approach may provide important and decision tool for planning immunotherapy.

KEY POINTS: • A radiomics-based model was built based on radiomics features and the presence of visceral organ involvement for prediction of outcomes in metastatic urothelial carcinoma treated with immunotherapy. • This prediction model demonstrated good prediction of treatment response and higher net benefit than no model in the independent validation set. • This radiomics-based model demonstrated significant associations with progression-free and overall survival between low-risk and high-risk groups.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Park KJ, Lee JL, Yoon SK, et al. Radiomics-based prediction model for outcomes of PD-1/PD-L1 immunotherapy in metastatic urothelial carcinoma. Eur Radiol. 2020. PMID: 32394281. doi:10.1007/s00330-020-06847-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。